Gloria Melanie, COO, reported an open-market or private sale at Immunovant, Inc. involving 3056.000000 shares for an estimated $134952.96. Reported holdings after the transaction were 219301.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
Chief Operating Officer
On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on August
18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is
mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Rep…
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 - $44.37 per share, inclusive. The Reporting Person undertakes to provide
to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with…
range set forth in this footnote to this Form 4.
0 other filings
0 recent txs